EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSOTSG00005045578
Gene Symbol: PSMD2
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSOTSG00005037069
Gene Symbol: PSMD2
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSOTSG00005007806
Gene Symbol: PSMD4
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSOTSG00005003223
Gene Symbol: PSMD4
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSOTSG00005023843
Gene Symbol: PSMD4B
1 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSOTSG00005005200
Gene Symbol: PSMC1
3 Cross references
30 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSOTSG00005039204
Gene Symbol: PSMC2
1 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSOTSG00005027740
Gene Symbol: PSMC3
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSOTSG00005022687
Gene Symbol: PSMC3
3 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSOTSG00005005787
Gene Symbol: PSMC4
1 Cross references
190 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSOTSG00005028626
Gene Symbol: PSMD1
1 Cross references
208 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSOTSG00005006157
Gene Symbol: PSMD1
1 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).